The expression of VISTA is increased after anti-CTLA4 therapy in patients with prostate cancer and after anti-PD1 therapy in metastatic melanoma patients, which could account for the acquired resistance to immune checkpoint therapy for tumors [21, 22]. This evidence concerns the gene VSIR and prostate carcinoma.